As part of my ETF DIY project, I analyzed $NOVO B (+2,99 %) analyzed them using my self-developed valuation system:
Moat: 5/5
- Market position: +
- Uniqueness / differentiability: +
- Switching costs: +
- Technological advantage: +
- Brand loyalty: +
Growth: 5/5
- Turnover & profit: +
- Scalability: +
- Industry trends: +
- Ability to innovate: +
- Geographic expansion / penetration: +
Risk: 3/5
- Regulatory & geopolitical: -
- Market risks: +
- Competitive situation: +
- Balance sheet quality: +
- Sales diversification: -
Dividend: 1/1
- Dividend yield >2.5% + Dividend growth
Faith: 0/1
- Stable company, but don't see the mega explosion in the future.
Total: 14/17
- Novo Nordisk is invested with a factor of 4.
If you are not yet familiar with my system and the ETF DIY project, just take a look at my profile.
The complete analysis and my thoughts on it can also be found on YouTube: